ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism

Sponsors

Lead Sponsor: Aldagen

Source Aldagen
Brief Summary

Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion. The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.

Detailed Description

Subjects will be hospitalized and undergo high doses of chemotherapy which will destroy the child's normal cells including their bone marrow (which forms blood cells) in order to prepare their body for the umbilical cord blood transplant. The cord blood transplant is intended to rescue your child's bone marrow from the bad effects of the procedure. The child will receive 80% of a standard cord blood transplant followed by 20% supplemental stem cell called ALD-101. The study will evaluate if these cells (ALD-101) will repopulate the bone marrow more rapidly after transplant. This would shorten the period of time that the transplanted subject would be at risk for infection and bleeding and would also decrease the number of red blood cell and platelet transfusions needed. ALD-101 has been used as a supplement to cord blood transplant in twenty-eight children with genetic diseases and malignancy in one previous clinical study that is on-going. The main purpose of this research study is to test whether a portion of cord blood cells that have been separated from a cord blood unit (ALD-101) will increase the speed at which normal levels of circulating blood cells are re-established after transplant. This is the experimental part of this study. ALD-101 is also being tested to see if it is safe.

Overall Status Terminated
Start Date March 2008
Completion Date November 2011
Primary Completion Date July 2011
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
To assess the efficacy of adjuvant therapy of ALD-101 in accelerating platelet engraftment in patients also receiving a standard unrelated UCBT for treatment of inherited metabolic diseases 180 Days
Secondary Outcome
Measure Time Frame
To assess the efficacy of ALD-101 in accelerating neutrophil engraftment 180 Days
To assess the safety of adjuvant therapy of ALD-101 in infusional toxicity, adverse events, and primary graft failure. 180 Days
Enrollment 40
Condition
Intervention

Intervention Type: Biological

Intervention Name: ALD-101

Description: A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).

Arm Group Label: I

Eligibility

Criteria:

Inclusion Criteria: - confirmed diagnosis of inherited metabolic diseases; including the following: - Hurler Syndrome (MPS I) - Hurler-Scheie Syndrome - Hunter Syndrome (MPS II) - Sanfilippo Syndrome A and B(MPS III) - Maroteaux-Lamy Syndrome (MPS VI) - Krabbe Disease (Globoid Leukodystrophy) - Metachromatic Leukodystrophy (MLD) - Adrenoleukodystrophy (ALD and AMN) - Sandhoff Disease - Tay Sachs Disease - Pelizaeus Merzbacher (PMD) - Niemann-Pick Disease - Alpha-mannosidosis - I-Cell Disease (ML II) - Fucosidosis - GM I Gangliosidosis - Canavan Disease - must be <16 years of age at the time of study enrollment - must have a good performance status (Lansky ≥80%) - must have adequate function of other organ systems including: kidney, liver, heart and lungs - must have given valid written informed consent - must have a minimum life expectancy of at least 6 months - must be determined to be a good candidate for a standard umbilical cord blood transplant - must have an IQ >70 or if too young for IQ testing the potential to reach this endpoint by age 5 Exclusion Criteria: - HIV, Hepatitis B and/or Hepatitis C positive - concurrently involved in any other clinical study that affects engraftment or immune reconstitution - uncontrolled seizures, apnea, evidence of aspiration pneumonia, or evidence of brain stem involvement - uncontrolled infections - prior allogeneic stem cell transplant with cytoreduction preparative therapy within 12 months of enrollment

Gender: All

Minimum Age: N/A

Maximum Age: 16 Years

Healthy Volunteers: No

Overall Official
Location
Facility:
Mattel Children's Hospital at UCLA | Los Angeles, California, 90095, United States
Mt. Sinai Medical Center | New York, New York, 27705, United States
Duke University | Durham, North Carolina, 27705, United States
Location Countries

United States

Verification Date

July 2014

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: I

Type: Experimental

Acronym UCBT-002
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov